Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicin...
Guardado en:
Autores principales: | Pearson S, Kietsiriroje N, Ajjan RA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea897ea817234a6793c6e8fcf10e6798 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021) -
Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019) -
Oral semaglutide: the innovation in type 2 diabetes management
por: M. V. Shestakova, et al.
Publicado: (2021) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)